Microbiome Therapeutics LLC, of Broomfield, Colo., reported top-line results from a proof-of-concept study testing whether investigational drug NM505, a combination of metformin plus the active ingredients in the firm's lead microbiome modulator, NM504, can improve the tolerability of metformin.